Tomorrow.Bio receives 5 million euros in seed financing

With its own ambulance fleet, medical partners and ambitious plans for resuscitation in the future, the start-up is making headlines. Now it is expanding into the USA with fresh funding.

Berlin, May 22, 2025 - Tomorrow.Bio, Europe's first cryonics startup based in Berlin, has closed a seed financing round of 5 million euros. The aim is to drive international expansion, primarily in the USA, as well as research and development in the field of cryopreservation. The round was led by the French VC Blast.Club and the German family office Truventuro (Nils Regge). Business angels and existing investors also participated.

Expansion to North America planned

In the next step, the company plans to set up locations in New York, California and Florida and establish local cryo teams there for the first time. Tomorrow.Bio's goal is to be the first company in the world to offer immediate cryopreservation via decentralized teams.

Tomorrow.Bio is at the forefront of visionary longevity concepts.

Nils Regge, Truventuro

Pioneering work in cryopreservation

Tomorrow.Bio was founded in 2020 by Dr. Emil Kendziorra, a former cancer researcher, and engineer Fernando Azevedo Pinheiro. The idea: deceased people are to be cryopreserved in a highly standardized medical and technological process immediately after death has been determined. The hope: future medical breakthroughs could one day make resuscitation possible.

Own ambulance fleet and emergency teams

Tomorrow.Bio has its own special ambulances in Berlin and Zurich, which are deployed immediately in the event of an emergency. The process begins immediately after death with oxygen supply, cardiac massage and gradual cooling of the body. A cryoprotectant solution replaces the body's own water to prevent the formation of ice crystals. The patients are stored in vacuum-insulated stainless steel tanks at -196 °C in cooperation with the European Biostasis Foundation (EBF) in Switzerland.

High demand despite speculative prospects

To date, Tomorrow.Bio has already cryopreserved 20 people and 10 animals. Over 800 other people have signed contracts, with a contract volume of more than 150 million euros. The procedures are thus attracting increasing interest. The longevity scene in particular, but also the tech community, seems to be open to the idea.

Emil and Fernando's vision is ambitious, but realistic. Tomorrow.Bio could become a medical pioneer of the future.

Anthony Bourbon, founder of Blast.Club

With the funding and US market entry, Tomorrow.Bio moves one step closer to its long-term vision: bridging death with technology to capitalize on future medical opportunities. For a growing segment of people worldwide, this idea no longer seems to be science fiction, but increasingly a real option. On the other hand, the news also shows that the VC scene in Berlin, which had already been declared dead, is far from over.